SESSION TITLE: Asthma I
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM
PURPOSE: Omalizumab (OMA), a humanized monoclonal anti-IgE antibody, is recommended by the GINA guidelines as a step 5 therapy for the treatment of persistent moderate-to-severe allergic asthma. However, there is limited data on the management of Chinese patients (pts) with OMA. We report here the effect of OMA on asthma and symptom control, use of rescue medication and quality of life (QOL) in Chinese pts with moderate-to-severe allergic asthma.